home / stock / cort / cort news


CORT News and Press, Corcept Therapeutics Incorporated

Stock Information

Company Name: Corcept Therapeutics Incorporated
Stock Symbol: CORT
Market: NASDAQ

Menu

CORT CORT Quote CORT Short CORT News CORT Articles CORT Message Board
Get CORT Alerts

News, Short Squeeze, Breakout and More Instantly...

CORT - Buy Recommendation Issued On CORT By Truist Financial

2024-05-02 17:30:02 ET Truist Financial analyst issues BUY recommendation for CORT on May 2, 2024 04:01PM ET. The previous analyst recommendation was Buy. CORT was trading at $25.06 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...

CORT - Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript

2024-05-01 23:42:02 ET Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Conference Call May 1, 2024 17:00 ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Wil...

CORT - Corcept Therapeutics GAAP EPS of $0.25 beats by $0.03, revenue of $146.81M beats by $5.61M

2024-05-01 16:52:34 ET More on Corcept Therapeutics Corcept Therapeutics: Key Catalysts Ahead Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript Corcept Therapeutics Q1 2024 Earnings Preview Corcept falls after phase 3 results on Cushin...

CORT - Expected US Company Earnings on Wednesday, May 1st, 2024

Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...

CORT - Corcept Therapeutics Q1 2024 Earnings Preview

2024-04-30 17:20:27 ET More on Corcept Therapeutics Corcept Therapeutics: Key Catalysts Ahead Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript Corcept falls after phase 3 results on Cushing's candidate doesn't include some data Corcep...

CORT - Corcept Completes Enrollment in Phase 4 CATALYST Trial

MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of th...

CORT - Corcept falls after phase 3 results on Cushing's candidate doesn't include some data

2024-04-22 11:22:23 ET More on Corcept Therapeutics Corcept Therapeutics: Key Catalysts Ahead Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript Corcept Therapeutics Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on Corcep...

CORT - US Companies Moving the Markets, Morning edition
Mon, Apr 22, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States Moolec Science SA (MLEC) rose 85.7% to $2.6 on volume of 50,077,650 shares SuperCom Ltd. (SPCB) rose 46.0% to $0.3212 on volume of 37,315,721 shares AGBA Group Holding Limited (AGBA) rose 35.2% to $1.69 on volume of 26,672,582 shares ...

CORT - Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing's Syndrome

MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of t...

CORT - (CORT) Investment Analysis and Advice

2024-04-20 13:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Next 10